Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

References related to functions published in Blood

PMID	Journal	Published Date	Author	Title
2451547	Blood	1988	Vercellotti GM et al.	Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage.
3006836	Blood	1986	Gay JC et al.	Modulation of neutrophil oxidative responses to soluble stimuli by platelet-activating factor.
2825844	Blood	1988	Gay JC and Stitt ES	Platelet-activating factor induces protein kinase activity in the particulate fraction of human neutrophils.
3663938	Blood	1987	Siess W and Lapetina EG	Phorbol esters sensitize platelets to activation by physiological agonists.
6282362	Blood	1982	Ingraham LM et al.	Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor.
6696992	Blood	1984	Hoffman DR et al.	Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts.
6947829	Blood	1982	Camussi G et al.	Release of platelet-activating factor from HL-60 human leukemic cells following macrophage-like differentiation.
22167755	Blood	2012	López-Sagaseta J et al.	sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove.